Neoadjuvant therapy for resectable colorectal cancer pulmonary oligometastases: a retrospective cohort study
NAT may confer a survival benefit in patients with resectable CRCPOM. Using an easy-to-use clinical risk score, patients with ≥ 1 risk factor are good candidates for initial NAT. The RECIST criteria are deemed suitable for the assessment of efficacy of NAT before lung metastasectomy.
Authors
- De-Ning Ma (ORCID: https://orcid.org/0000-0002-5560-8078)
- Guohui Xu
- Yuping Zhu (ORCID: https://orcid.org/0000-0001-5045-3380)
- Yong Shao (ORCID: https://orcid.org/0000-0001-6591-8072)
- Yanmei Cai (ORCID: https://orcid.org/0000-0002-0592-3766)
Institutions
- Chinese Academy of Sciences (CN)
- Wenzhou Medical University (CN)
- Zhejiang Cancer Hospital (CN)
- Jiangxi Pingxiang People's Hospital (CN)
Publication Details
- Journal
- International Journal of Colorectal Disease
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1007/s00384-025-04986-8
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- Medical Science and Technology Project of Zhejiang Province
- Science and Technology Program of Zhejiang Province